Inhalation Anesthesia Market size is estimated to be valued at USD 1,483.6 Mn in 2025 and is expected to reach USD 2,129.7 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 5.3% from 2025 to 2032.
The global Inhalation Anesthesia Market Demand is experiencing strong growth due to the increasing prevalence of chronic disease and growing geriatric (aging) population around the world. However, factors such as side-effects of inhaler anesthesia drugs and increase in demand or adoption of generics are expected to hamper the market growth.
|
Event |
Description and Impact |
|
Global Healthcare Supply Chain Disruptions |
|
|
Technological Developments and Innovations in Anesthesia Delivery Systems |
|
|
Heightened Environmental and Regulatory Focus on Greenhouse Gas Emissions in Healthcare |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Prescribers’ choices for inhalation anesthetics are influenced by clinical efficacy, patient profiles, safety, cost, institutional protocols, and environmental considerations. Usage spans three key treatment phases: induction, maintenance, and emergence, each with distinct anesthetic requirements.
By product, Sevoflurane is expected to account for major share of 56.4% in the global inhalation anesthesia market value over the forecast period, driven primarily by the increasing number of surgeries worldwide.
Sevoflurane is widely used for the induction and maintenance of anesthesia in pediatric patients, making it a preferred choice in hospitals and surgical centers. Its rapid onset, minimal airway irritation, and favorable recovery profile make it particularly effective in pediatric and outpatient settings.
By application, the Induction segment is anticipated to lead the inhalation anesthesia market during the forecast period. This growth is fueled by the rising demand for fast-acting inhalation anesthetics that offer effective onset during the initial phase of surgery. Inhaled anesthetics like Sevoflurane and Desflurane are increasingly being used for their ability to deliver smooth and rapid induction, especially in pediatric and ambulatory settings where IV access may be limited or delayed.
From the perspective of end user, Hospitals are expected to capture the largest the Inhalation Anesthesia Market Share throughout the forecast period. The rise in chronic illnesses such as cardiovascular, respiratory, and neurological disorders has led to a surge in surgeries, particularly among the growing elderly population. Hospitals, being the primary centers for major surgical procedures, continue to demand high volumes of inhalation anesthetics to manage surgical caseloads efficiently.
To learn more about this report, Download Free Sample
North America is projected to dominate the global Inhalation Anesthesia Market outlook, accounting for 44.9% share during the forecast period. This leadership is driven by the increasing number of surgeries, a rise in emergency incidents and road accidents, and a growing geriatric population highly susceptible to chronic diseases. Aging is a significant risk factor for many chronic conditions, including heart disease, cancer, and diabetes.
According to the Centers for Disease Control and Prevention (CDC), these chronic diseases are the leading causes of death and disability in the U.S., with 6 in 10 Americans living with at least one chronic disease. The presence of strong healthcare infrastructure and rising surgical procedures in the region further boost the demand for inhalation anesthetics.
Asia Pacific is expected to witness substantial growth in the Inhalation Anesthesia Market forecast period. This growth is fueled by the increasing burden of chronic diseases, expanding geriatric populations, a rise in road accidents, and a surge in surgical procedures. For instance, according to Peertechz Publications, over 18.8 million surgeries were performed in public health facilities in India during 2019-20, including around 4.85 million major surgeries and 14 million minor surgeries.
The U.S. continues to lead the North American inhalation anesthesia market, driven by a high volume of surgical procedures and a large aging population prone to chronic diseases. Investments in healthcare infrastructure and rising emergency cases also contribute to the demand for efficient anesthetic agents. Continued focus on improving surgical outcomes and patient safety is expected to fuel the adoption of advanced inhalation anesthesia products.
India is emerging as a key growth market within the Asia Pacific region, propelled by increasing surgical volumes and a rising incidence of chronic diseases. Government initiatives to improve healthcare infrastructure and expand access to surgical care are accelerating the use of inhalation anesthetics.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 1,483.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.3% | 2032 Value Projection: | USD 2,129.7 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Abbvie Inc., Novartis AG, Piramal Enterprises Ltd., Hikma Pharmaceuticals Plc, Fresenius SE & CO. KGaA, Baxter International Inc., Troikaa Pharmaceuticals, Ltd., Halocarbon Products Corporation, Jiangsu Hengrui Medicine Co., Ltd., Lunan Pharmaceutical Group Co. Ltd., among others. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Sevoflurane is the most widely used inhalation anesthetic, owing to its therapeutic advantages and low cost. It is useful in children and adults for induction and maintenance of anesthesia in inpatient surgery and outpatient surgery, and is given before surgery to make induction of general anesthesia drugs substantially easier. It is administered without the use of intravenous route and is ideal for people with asthma and sensitized air passages. Thus, there is an increase in demand for Sevoflurane, and this trend is expected to continue over the forecast period.
Players in the market are focusing on developing and launching novel products to meet increasing demand for inhalation anesthesia worldwide. In January 2019, Sandoz International announced the launch of Desflurane liquid as an inhalation agent for the induction and maintenance of anesthesia, required for inpatient and outpatient surgery in adults and pediatric patients in the U.S. It was the first generic of Suprane in the U.S.
One of the key factors expected to augment the growth of the global inhalation anesthesia market over the forecast period is the increasing prevalence of chronic disease, such as heart disease and cancer across the world. Such a high burden of chronic diseases leads to an increase in the number of surgeries and is expected to fuel the market growth.
According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death across the globe, taking an estimated 17.9 million lives each year, driving the growth of the market.
Another factor which is driving growth of the global inhalation anesthesia market is the growing geriatric (aging) population around the world. For instance, the ageing population tends to have a higher prevalence of chronic diseases. People age 65 and older are more likely than younger people to suffer from chronic disease. According to the World Health Organization (WHO), by 2030, one in six people in the world will be aged 60 years or over, and by 2050, the world’s population of people aged 60 years and older will double (2.1 billion).
Increase in demand or consumption of inhalation anesthesia is expected to offer significant growth opportunities for players in the global inhalation anesthesia market. For instance, with the increase in burden of chronic disease and increasing number of surgical procedures, the demand or the use of inhalation anesthesia is also increasing with the rapid pace. In February 2022, Sedana Medical AB announced the launch of Sedaconda (isoflurane) in Germany. Sedaconda has received national approvals in around 15 countries, and is also expected to receive national approvals in Switzerland, Poland, Italy, and the United Kingdom.
*Definition: Inhalation anesthetics (nitrous oxide, halothane, isoflurane, desflurane, sevoflurane, most commonly used agents in practice today) are used for induction and maintenance of general anesthesia in the operating room.
Share
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
